Pfizer- C4391026
Brief Summary
An Interventional, Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase 3 Study of Atirmociclib (PF-07220060) Plus Giredestrant Compared to Giredestrant Monotherapy as Adjuvant Treatment in Adult Participants With Estrogen Receptor (ER)-Positive, HER2-Negative Early-Stage Breast Cancer With Medium or High Risk of Recurrence (FourLight-4)
Official Title
FOURLIGHT-4
Condition
A Phase 3 Study of Atirmociclib in Combination with Giredestrant in Adult Participants with ER-positive, HER2-negative Early-stage Breast Cancer (FourLight-4).
